Treatments and compositions targeting α-synuclein: a patent review (2010-2016)

References

• Goedert M. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. 2015;349:1255555.
   PubMed Web of Science ®Google Scholar
• Benskey MJ, Perez RG, Manfredsson FP. The contribution of alpha synuclein to neuronal survival and function - implications for Parkinson’s disease. J Neurochem. 2016;137:331–359.
   PubMed Web of Science ®Google Scholar
• Dehay B, Bourdenx M, Gorry P, et al. Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015;14:855–866.
   PubMed Web of Science ®Google Scholar
• Gallegos S, Pacheco C, Peters C, et al. Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson’s disease. Front Neurosci. 2015;9:59.
   PubMed Web of Science ®Google Scholar
• Sardi SP, Shihabuddin L, Cheng S Compositions and methods for treating proteinopathies.WO/2014/071282. 2014.
   Google Scholar
• Krainc D, Mazzulli JR Treatment of proteinopathies.US2014288093 (A1). 2014.
   Google Scholar
• Arancio O, Deng S, Landry D, et al. Histone acetyltransferase activators and uses thereof.WO2015153410 (A1) 2015.
   Google Scholar
• Hashimoto M, Sekiyama K, Takamatsu Y, et al. Method for treating and/or preventing neurodegenerative disease by adiponectin receptor agonist.US2013157950 (A1). 2013.
   Google Scholar
• Manning-Bog AB, Schüle B, Langston JW, et al. 20150044193 compositions and methods for the treatment of altered a-synuclein function.US20150044193 2015.
   Google Scholar
• Ringe D, Petsko GA, Selkoe DJ, et al. Tetrameric alpha-synuclein as biomarkers.US2013309690 (A1). 2013.
   Google Scholar
• Chilcote TJ, Goldstein J, Anderson JP, et al. Truncated fragments of alpha-synuclein in lewy body disease.JP2011033633 (A). 2011.
   Google Scholar
• Ringe D, Petsko GA, Hoang QQ 20130316384 Ice-cleaved alpha-synuclein as a biomarker.WO/2012/061786. 2015.
   Google Scholar
• Yu S, Yang W, Li X Method for detecting hemoglobin-combined phosphorylated alpha-synuclein.CN104215777 (A) 2014.
   Google Scholar
• Yu S, Yin N, Yang W, et al. Method for detecting capability of subject body fluid for promoting phosphorylation modification of disease related protein in vitro.CN103954763 (A). 2014.
   Google Scholar
• Nordström E, Kasrayan A, Ekberg M, et al. Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson’s disease, dementia with lewy bodies and other alpha-synucleinopathies.US2015139900 (A1).2015.
   Google Scholar
• Tu Z, Mach R, Yu L, et al. Tricyclic heteroaromatic compounds as alpha-synuclein ligands.US2013315825 (A1). 2013.
   Google Scholar
• Kim JR, Hernandez M Conformational-switching fluorescent protein probe for detection of alpha synuclein oligomers.US2015017739 (A1). 2015.
   Google Scholar
• Gobbi L, Knust H, Koerner M, et al. Imidazo1,2-a.pyridin-7-amines as imaging tools.CA2920068 (A1). 2015.
   Google Scholar
• Morgan JR, Bitan G, Busch DJ Treatment of spinal cord injury or traumatic brain injury by inhibition of amyloidogenic proteins and synuclein protein accumulation or aggregation.US2015202222 (A1). 2015.
   Google Scholar
• Chilcote TJ, Goldstein J, Anderson JP, et al. Antibodies to alpha synuclein.US2013072663 (A1). 2013.
   Google Scholar
• Gendelman H, Mosley R Methods and compositions for inhibiting diseases of the central nervous System.WO/2013/173827. 2013.
   Google Scholar
• Shaltiel-Karyo R, Gazit E Compositions and methods for prevention and treatment of neurodegenerative diseases.WO/2010/103515. 2010.
   Google Scholar
• Cohen D, Nabirochkin S, Chumakov I New therapeutic approaches for treating Parkinson’s disease.US2015246044 (A1). 2015.
   Google Scholar
• Lannfelt L Prevention and treatment of Alzheimer’s disease.US2012156222 (A1). 2012.
   Google Scholar
• Anderson JP, Banducci K, Basi GS, et al. Alpha-synuclein kinase.US2011207796 (A1). 2011.
   Google Scholar
• Jara CS, Shahnawaz M, Lebovitz RM, et al. Detection of misfolded alpha synuclein protein.WO2016040905 (A1). 2016.
   Google Scholar
• Yu S, Yin N, Yang W, et al. Method for detecting in vitro capability of subject body fluid to promote polymerization of disease associated protein.CN103983778 (A). 2014.
   Google Scholar
• Hu H, Xie Y, Zhou C Substances regulating alpha-synuclein accumulation and its pharmaceutical application.CN102690244 (A). 2012.
   Google Scholar
• Sidhu A Targeting gsk-3beta for the treatment of Parkinson’s disease.WO2012170657 (A1). 2012.
   Google Scholar
• Mar WC, Shin JH, Ham AR Composition comprising sesquiterpene compounds for prevention or treatment of degenerative brain diseases.KR101092620 (B1). 2011.
   Google Scholar
• Hashimoto K, Sekiyama K, Takamatsu Y, et al. 2013234167 pharmaceutical composition for treating and/or preventing neurodegenerative disease and screening method for active ingredient thereof.JP2013234167. 2013.
   Google Scholar
• Law YK, Wu A-G, Wong KW, et al. Active autophagic fraction from radix polygalae for treatment of neurodegenerative diseases.AU2014101057 (A4). 2014.
   Google Scholar
• Cao C, Lin X Methods, antibodies, and vaccines utilizing Epitopes of alpha synuclein for treatment of Parkinson’s disease.WO2015179867 (A1). 2015.
   Google Scholar
• Hinkle G, Bumcrot D Compositions and methods for inhibition of SNCA.WO2012027713 (A2). 2012.
   Google Scholar
• Yonezawa AI. Adsorbent of synuclein and system for removing synuclein by adsorption.JP2012193112 (A). 2012.
   Google Scholar
• Wüllner U, Schmitt I Analysis of the methylation pattern of the alpha-synuclein gene from DNA of peripheral blood monocytes for diagnosing Parkinson’s disease.WO/2012/101228. 2012.
   Google Scholar
• Yu S, Yang W, Li X Method for detecting hemoglobin-combined alpha-synuclein.CN104215779 (A). 2014.
   Google Scholar
• El-Agnaf O, Parnetti L, Calabresi P Method for diagnosis.US2013183278 (A1). 2013.
   Google Scholar
• Sharon R Method for the assay of synucleins.US2015024419 (A1). 2015.
   Google Scholar
• An SS, Shim KH, Baek EG Diagnostic method for synucleinopathy and diagnostic kit therefor.KR20140018691 (A). 2014.
   Google Scholar
• West T, Paoletti AC Methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders and associated processes.WO/2013/043745. 2013.
   Google Scholar
• Schmidt B, Kieser D, Bolaender A, et al. Compounds for diagnosing neurodegenerative diseases at the retina.WO2012041292 (A2). 2012.
   Google Scholar
• Lindquist SL, Gitler AD, Cashikar A, et al. Modulators of alpha-synuclein toxicity.US2013244903 (A1). 2013.
   Google Scholar
• Mazzio E, Soliman K, Mazzio EA, et al. Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson’s disease.US2010150895 (A1). 2010.
   Google Scholar
• Davis J Method for detecting autoantibodies.US2015219579 (A1). 2015.
   Google Scholar
• Jesko H, Okada T, Strosznajder RP, et al. Sphingosine kinases modulate the secretion of amyloid β precursor protein from SH-SY5Y neuroblastoma cells: the role of α-synuclein. Folia Neuropathol. 2014;52:70–78.
   PubMed Web of Science ®Google Scholar
• Czapski GA, Gąssowska M, Wilkaniec A, et al. Extracellular alpha-synuclein induces calpain-dependent overactivation of cyclin-dependent kinase 5 in vitro. FEBS Lett. 2013;587:3135–3141.
   PubMed Web of Science ®Google Scholar
• Kanaan NM, Manfredsson FP. Loss of functional alpha-synuclein: a toxic event in Parkinson’s disease? J Parkinsons Dis. 2012;2:249–267.
   PubMedGoogle Scholar
• Da Costa C C, Paitel E, Vincent B, et al. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson’s disease. J Biol Chem. 2002;277:50980–50984.
   PubMed Web of Science ®Google Scholar
• Kim J-Y, Jeon BS, Kim H-J, et al. Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway. Neural Regen Res. 2013;8:3269–3274.
   PubMed Web of Science ®Google Scholar
• Gąssowska M, Czapski GA, Pająk B, et al. Extracellular α-synuclein leads to microtubule destabilization via GSK-3β-dependent Tau phosphorylation in PC12 cells. PLoS ONE. 2014;9:e94259.
   PubMed Web of Science ®Google Scholar
• Caraveo G, Auluck PK, Whitesell L, et al. Calcineurin determines toxic versus beneficial responses to α-synuclein. Proc Natl Acad Sci USA. 2014;111:E3544–E3552.
   Google Scholar
• Jain MK, Bhat R. Modulation of human α-synuclein aggregation by a combined effect of calcium and dopamine. Neurobiol Dis. 2014;63:115–128.
   PubMed Web of Science ®Google Scholar
• Adamczyk A, Strosznajder JB. Alpha-synuclein potentiates Ca2+ influx through voltage-dependent Ca2+ channels. Neuroreport. 2006;17:1883–1886.
   PubMed Web of Science ®Google Scholar
• Kazmierczak A, Strosznajder JB, Adamczyk A. Alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. Neurochem Int. 2008;53:263–269.
   PubMed Web of Science ®Google Scholar
• Betzer C, Movius AJ, Shi M, et al. Identification of synaptosomal proteins binding to monomeric and oligomeric α-synuclein. PLoS ONE. 2015;10:e0116473.
   PubMed Web of Science ®Google Scholar
• Ciron C, Lengacher S, Dusonchet J, et al. Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet. 2012;21:1861–1876.
   PubMed Web of Science ®Google Scholar
• Yakunin E, Kisos H, Kulik W, et al. The regulation of catalase activity by PPAR γ is affected by α-synuclein. Ann Clin Transl Neurol. 2014;1:145–159.
   PubMed Web of Science ®Google Scholar
• Beyer K, Ariza A. Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol. 2013;47:509–524.
   PubMed Web of Science ®Google Scholar
• Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci. 2014;34:9441–9454.
   PubMed Web of Science ®Google Scholar
• Dettmer U, Newman AJ, Soldner F, et al. Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun. 2015;6:7314.
   PubMed Web of Science ®Google Scholar
• Volpicelli-Daley LA, Gamble KL, Schultheiss CE, et al. Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes. Mol Biol Cell. 2014;25:4010–4023.
   PubMed Web of Science ®Google Scholar
• Bate C, Williams A. α-Synuclein-induced synapse damage in cultured neurons is mediated by cholesterol-sensitive activation of cytoplasmic phospholipase A2. Biomolecules. 2015;5:178–193.
   PubMed Web of Science ®Google Scholar
• Tönges L, Szegö EM, Hause P, et al. Alpha-synuclein mutations impair axonal regeneration in models of Parkinson’s disease. Front Aging Neurosci. 2014;6:239.
   PubMed Web of Science ®Google Scholar
• Iljina M, Garcia GA, Horrocks MH, et al. Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. Proc Natl Acad Sci USA. 2016;113:E1206–E1215.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Suk J-E, Bae E-J, et al. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun. 2008;372:423–428.
   PubMed Web of Science ®Google Scholar
• Bliederhaeuser C, Grozdanov V, Speidel A, et al. Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathol. 2016;131:379–391.
   PubMed Web of Science ®Google Scholar
• Gardai S, Johnston JA Phagocytic activity as a marker of synucleinopathic disease.AU2011336895 (A1). 2013.
   Google Scholar
• Bae E-J, Yang N-Y, Song M, et al. Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein. Nat Commun. 2014;5:4755.
   PubMed Web of Science ®Google Scholar
• Pukass K, Richter-Landsberg C. Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular α-synuclein in oligodendrocytes. J Mol Neurosci. 2014;52:339–352.
   PubMed Web of Science ®Google Scholar
• Kalivendi SV, Yedlapudi D, Hillard CJ, et al. Oxidants induce alternative splicing of alpha-synuclein: implications for Parkinson’s disease. Free Radic Biol Med. 2010;48:377–383.
   PubMed Web of Science ®Google Scholar
• Armstrong D, Davies W, Ferlito VC, et al. Behavioural assay.WO/2016/051157. 2016.
   Google Scholar
• Mbefo MK, Fares M-B, Paleologou K, et al. Parkinson disease mutant E46K enhances α-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo. J Biol Chem. 2015;290:9412–9427.
   PubMed Web of Science ®Google Scholar
• Liu G, Chen M, Mi N, et al. Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains. Neurobiol Aging. 2015;36:2649–2659.
   PubMed Web of Science ®Google Scholar
• Van Rompuy A-S, Oliveras-Salvá M, Van der Perren A, et al. Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration. Mol Neurodegener. 2015;10:23.
   PubMed Web of Science ®Google Scholar
• McFarland MA, Ellis CE, Markey SP, et al. Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics. 2008;7:2123–2137.
   PubMed Web of Science ®Google Scholar
• Samuel F, Flavin WP, Iqbal S, et al. Effects of serine 129 phosphorylation on α-synuclein aggregation, membrane association, and internalization. J Biol Chem. 2016;291:4374–4385.
   PubMed Web of Science ®Google Scholar
• Wen T, Zhang S Novel use of fruit fly gene lk6.CN103251959 (A). 2013.
   Google Scholar
• Xu Y, Deng Y, Qing H. The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson’s disease. J Neurochem. 2015;135:4–18.
   PubMed Web of Science ®Google Scholar
• Deas E, Cremades N, Angelova PR, et al. Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson’s disease. Antioxid Redox Signal. 2016;24:376–391.
   PubMed Web of Science ®Google Scholar
• Chung CY, Khurana V, Auluck PK, et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science. 2013;342:983–987.
   PubMed Web of Science ®Google Scholar
• Broe M, Shepherd CE, Mann DMA, et al. Insoluble alpha-synuclein in Alzheimer’s disease without Lewy body formation. Neurotox Res. 2005;7:69–76.
   PubMed Web of Science ®Google Scholar
• Masliah E, Spencer B, Rockenstein E, et al. Compounds for reversing and inhibiting protein aggregation, and methods for making and using them.US2011223240 (A1). 2011.
   Google Scholar
• Su C, Niu P. Low doses of single or combined agrichemicals induces α-synuclein aggregation in nigrostriatal system of mice through inhibition of proteasomal and autophagic pathways. Int J Clin Exp Med. 2015;8:20508–20515.
   PubMed Web of Science ®Google Scholar
• Bentea E, Van der Perren A, Van Liefferinge J, et al. Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein. Front Behav Neurosci. 2015;9:68.
   PubMed Web of Science ®Google Scholar
• Pukaß K, Goldbaum O, Richter-Landsberg C. Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of α-synuclein in oligodendroglial cells. J Neurochem. 2015;135:194–205.
   PubMed Web of Science ®Google Scholar
• Lopes da Fonseca T, Villar-Piqué A, Outeiro TF. The interplay between alpha-synuclein clearance and spreading. Biomolecules. 2015;5:435–471.
   PubMed Web of Science ®Google Scholar
• Kawakami F, Suzuki M, Shimada N, et al. Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β. FEBS J. 2011;278:4895–4904.
   PubMed Web of Science ®Google Scholar
• Mak S, Schüle B, Langston JW 20150037257 Compositions and methods for high-throughput screening in skin fibroblasts with an alpha-synuclein triplication.US20150037257. 2015.
   Google Scholar
• Majbour NK, Vaikath NN, van Dijk KD, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. Mol Neurodegener. 2016;11:7.
   PubMed Web of Science ®Google Scholar
• Zhou J, Broe M, Huang Y, et al. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson’s disease. Acta Neuropathol. 2011;121:695–704.
   PubMed Web of Science ®Google Scholar
• Simonsen AH, Kuiperij B, El-Agnaf OMA, et al. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med. 2016;10:19–34.
   PubMed Web of Science ®Google Scholar
• Bowser R, Jeromin A, Shaw G Traumatic brain injury and neurodegenerative biomarkers, methods, and systems.WO2015157300 (A1). 2015.
   Google Scholar
• Wang X, Yu S, Li F, et al. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease. Neurosci Lett. 2015;599:115–119.
   PubMed Web of Science ®Google Scholar
• Aasly JO, Johansen KK, Brønstad G, et al. Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci. 2014;6:248.
   PubMed Web of Science ®Google Scholar
• Hansson O, Hall S, Ohrfelt A, et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther. 2014;6:25.
   PubMed Web of Science ®Google Scholar
• Delenclos M, Jones DR, McLean PJ, et al. Biomarkers in Parkinson’s disease: advances and strategies. Parkinsonism Relat Disord. 2016;22(Supplement 1):S106–S110.
   Google Scholar